Free Trial
NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

Trevena logo
$0.07 0.00 (0.00%)
As of 10/12/2026 02:57 PM Eastern

About Trevena Stock (NASDAQ:TRVN)

Advanced

Key Stats

Today's Range
$0.07
▼
$0.07
50-Day Range
$0.00
▼
$0.07
52-Week Range
$0.00
▼
$1.50
Volume
833 shs
Average Volume
727 shs
Market Capitalization
$63.29 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on developing medicines for central nervous system disorders, with an emphasis on addressing the limitations of existing opioid and other neurological therapies. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an intravenous opioid approved by the U.S. Food and Drug Administration for the management of acute pain in adults severe enough to require an intravenous opioid analgesic. OLINVYK was designed to provide pain relief while potentially reducing certain adverse effects associated with conventional opioids, although it carries the risks and precautions associated with opioid medicines.

The company has also researched additional compounds for neurological conditions, including investigational therapies intended for disorders such as pain and epilepsy. Trevena’s commercial activities have primarily focused on the United States, while its development and licensing efforts have included relationships intended to support access to international markets. Information about the company’s current leadership and operating status may change over time.

AI Generated. May Contain Errors.

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRVN Stock News Headlines

Trevena Inc.
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Trevena, Inc. (TRVN) - Yahoo Finance
See More Headlines

TRVN Stock Analysis - Frequently Asked Questions

Trevena's stock was trading at $0.0120 at the start of the year. Since then, TRVN shares have increased by 450.0% and is now trading at $0.0660.

Trevena, Inc. (NASDAQ:TRVN) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($9.25) by $9.02. The biopharmaceutical company earned $0.33 million during the quarter.

Trevena's stock reverse split on Tuesday, August 13th 2024.The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Sorrento Therapeutics (SRNE), Novavax (NVAX), NIO (NIO), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Micron Technology (MU) and SCYNEXIS (SCYX).

Company Calendar

Last Earnings
8/08/2024
Today
10/13/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TRVN
CIK
1429560
Fax
N/A
Employees
23
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($47.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.29 million
Net Margins
N/A
Pretax Margin
-6,222.30%
Return on Equity
N/A
Return on Assets
-119.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.42
Quick Ratio
2.42

Sales & Book Value

Annual Sales
$443 thousand
Price / Sales
0.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($11.07) per share
Price / Book
-0.01

Miscellaneous

Outstanding Shares
959,000
Free Float
841,000
Market Cap
$63.29 thousand
Optionable
No Data
Beta
-1.99

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:TRVN) was last updated on 10/12/2026 by MarketBeat.com Staff.
From Our Partners